It’s August 2009 and in the last 12 months, Lou Bock‘s portfolio has had some impressive success. He talks about how Zogenix, Horizon Therapeutics, Somaxon, Prestwick Pharmaceuticals and Orexigen have all done well. The Scale Venture Partners Managing Director has ...
FDA tagged posts:
September 28th, 2009 | Jennifer Jones